Press Release

Printer Friendly Version View printer-friendly version
« Back
Aptose to Participate in Upcoming Investor Conferences in March 2019

SAN DIEGO and TORONTO, March 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:

31st Annual ROTH Conference
  Time:  
Date:  
Location:
Format:
8:30 a.m. PDT
Tuesday, March 19, 2019
The Ritz Carlton, Laguna Niguel, CA
Panel Discussion: New BTK Drugs on the Block
     
Oppenheimer 29th Annual Healthcare Conference
  Time:  
Date:  
Location:
Live webcast:
9:10 a.m. EDT
Wednesday, March 20, 2019 
The Westin Grand Central, New York, NY
Link

The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor being developed to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.

For further information, please contact: For further information, please contact:

Aptose Biosciences
Greg Chow
Senior Vice President, CFO
650-718-5028
gchow@aptose.com
SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com
   
LifeSci Advisors, LLC
Daniel Ferry
Managing Director
617-535-7746
Daniel@lifesciadvisors.com
 

Aptose Biosciences Inc. logo

Source: Aptose Biosciences, Inc.